Mszros M, Phan THM, Vigh JP, Porkolb G, Kocsis A, Pli EK, et al
Small Intestinal Bacterial Overgrowth (SIBO) can lead to intestinal permeability and contribute to digestive symptoms
Summary: N-acetylcysteine (NAC) is not currently recommended by NICE or MHRA for treating fatty liver disease, though it may theoretically support liver health by replenishing glutathione and reducing oxidative stress
GIP, in addition to GLP-1, enhances insulin release after meals, reduces hunger, and increases fat metabolism
"And it's not because of any magic it's because these are natural substances that our bodies make and are familiar with, so that's what gives them this incredible safety profile." The FDA, however, has publicly stated that there is not enough evidence from human clinical trials on the safety or efficacy of these drugs